## In the Specification

On page 1, after the title, please add the following paragraph:

## CROSS-REFERENCE TO RELATED APPLICATIONS

(Abandonel)

This application is a Continuation of U.S. Patent Application Serial No. 09/433,391, filed November 3,1999, which claims the priority benefit of U.S. Provisional Patent Application No. 60/106,795, filed November 3,1998, each of which is incorporated by reference herein in it's entirety.

Please insert the attached paper copy of the "Sequence Listing" after the last page of the specification.

My 1-9-07 Examinary

FIG. 1E is a schematic representation of a GM-CSF-encoding adenovirus vector (AV-GM-CSF) useful in methods and vaccines of the present invention;

5

FIG. 1F is a schematic representation of a recombinant adeno-associated viral (AAV) vector plasmid (SSV9/MD2-hGM) useful in methods and vaccines of the present invention;

10

FIG. 1G is a schematic representation of a recombinant lentivirus vector containing a GM-CSF expression cassette flanked by HIV LTRs, useful in the methods and vaccines of the present invention;

15

FIG. 1H is a schematic representation of an HSV-1-based vector containing a GM-CSF expression cassette replacing the ICP22 HSV gene, useful in the methods and vaccines of the present invention;

20

FIG. 1I is a schematic representation of an SV-40-based plasmid (pSV HD GM-CSFII) including a GM-CSF expression cassette, the SV-40 origin of replication, and viral late genes, useful in the methods and vaccines of the present invention;

25

FIG. 1J is a schematic representation of a vaccinia virus expression cassette including a (500 10 NO:1 mod vaccinia virus promoter and termination sequence, 500 10 NO:2) useful in the methods and vaccines of the present invention;